Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 14/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19782880 | 0.93 | DHODH (0.48) | DHODHSYKMEN1MAPTKMT2A | |
| SCHEMBL15993448 | 0.87 | DHODH (0.53) | DHODHMEN1MAPTKMT2AKDM4E | |
| SCHEMBL29078713 | 0.86 | DHODH (0.56) | DHODHMEN1MAPTKMT2AP2RY1 | |
| SCHEMBL15993345 | 0.84 | DHODH (0.58) | DHODHMEN1MAPTKMT2ACYP1A2 | |
| SCHEMBL15993447 | 0.80 | DHODH (0.54) | DHODHMEN1MAPTKMT2AKDM4E | |
| SCHEMBL21245761 | 0.80 | CDC7 (0.56) | DHODHMEN1MAPTKMT2AKDM4E | |
| SCHEMBL15993418 | 0.79 | DHODH (0.53) | DHODHMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL19783106 | 0.79 | DHODH (0.53) | DHODHMEN1MAPTKMT2AKDM4E | |
| SCHEMBL19782992 | 0.77 | DHODH (0.56) | DHODHMEN1MAPTKMT2AKDM4E | |
| SCHEMBL18230366 | 0.76 | DHODH (0.58) | DHODHMEN1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913734-B2 | Substituted aminothiazoles | BARUCH S. BLUMBERG INSTITUTE | 2021-02-09 | — | — | US | disclosed |
| US-20190241552-A1 | SUBSTITUTED AMINOTHIAZOLES | BARUCH S. BLUMBERG INSTITUTE | 2019-08-08 | — | — | US | disclosed |
| WO-2018013508-A1 | SUBSTITUTED AMINOTHIAZOLES | BARUCH S. BLUMBERG INSTITUTE (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913734-B2 | Substituted aminothiazoles | ABAT, AADAT, BCAT1 | DHODH 329/4885SYK 1433/4885MEN1 2492/4885 |
| US-20190241552-A1 | SUBSTITUTED AMINOTHIAZOLES | ABAT, AADAT, BCAT1 | DHODH 329/4885SYK 1433/4885MEN1 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.